Moderna, Inc.
$200
−1.32% day
The Massachusetts biotech built on messenger RNA, the technology behind its Covid-19 vaccine. As Covid sales have shrunk, its value has come to rest on whether mRNA works against cancer and other diseases.
Oct 23 · $199.95 · +9.8% vs the window’s open
the numbers23
| when | value | change |
|---|---|---|
| Sep 23low | $182.11 | |
| Sep 24 | $194.82 | +7.0% |
| Sep 25 | $198.88 | +2.1% |
| Sep 28 | $197.28 | −0.8% |
| Sep 29 | $203.46 | +3.1% |
| Sep 30 | $192.57 | −5.4% |
| Oct 1 | $188.94 | −1.9% |
| Oct 2 | $190.01 | +0.6% |
| Oct 5 | $203.21 | +6.9% |
| Oct 6 | $187.46 | −7.8% |
| Oct 7 | $196.48 | +4.8% |
| Oct 8 | $197.00 | +0.3% |
| Oct 9 | $225.00 | +14.2% |
| Oct 12 | $213.74 | −5.0% |
| Oct 13 | $216.25 | +1.2% |
| Oct 14 | $226.30 | +4.6% |
| Oct 15 | $236.50 | +4.5% |
| Oct 16 | $218.01 | −7.8% |
| Oct 19 | $226.89 | +4.1% |
| Oct 20 | $242.08 | +6.7% |
| Oct 21high | $245.81 | +1.5% |
| Oct 22 | $202.63 | −17.6% |
| Oct 23latest | $199.95 | −1.3% |
Lately
Phase 3 results for intismeran autogene, the personalised mRNA vaccine Moderna and Merck give alongside Keytruda, came out before their scheduled presentation: it cut melanoma relapse or death 42%. Each dose is built from the patient's own tumour mutations. The shares had climbed into the reveal, then slid as investors read the result as a disappointment.